FDA Office Of New Drug Restructuring To Include OTC Resource Reallocation
This article was originally published in The Tan Sheet
Executive Summary
FDA's Office of New Drugs restructuring will more efficiently allocate the agency's resources and staff, particularly with respect to OTCs, Director John Jenkins, MD, said